GNOM vs IBB: Grades, Fees and Holdings Compared

Global X Genomics & Biotechnology ETF

GNOMDNasdaq

iShares Biotechnology ETF

IBBANasdaq

Overlap

23.9%by weight

Expense ratio

IBB −0.06pt a year

GNOM0.50%IBB0.44%

Avg volume · 30D

IBB 47.1×the volume

GNOM35KIBB1.65M

5Y return · a year

IBB +10.5pt

GNOM−3.8%IBB+6.7%

GNOM vs IBB Performance

Oct 29, 2021 – Oct 30, 2026

−17.5%GNOM+38.1%IBB

Expense ratio: GNOM 0.50%; IBB 0.44%, better
Fund size: GNOM $113M; IBB $11.5B
1Y total return: GNOM +55.3%, better; IBB +36.8%
Yield (12M): GNOM 0.93%, better; IBB 0.16%
Holdings: GNOM 50; IBB 243
Avg volume (30D): GNOM 35K sh; IBB 1.65M sh, better
NAV per share: GNOM $69.50; IBB $217.59
52W range

ETF.net Grade

Pillar letters and Scores for GNOM, IBB, with each pillar’s weight
Pillar	GNOM	IBB
Cost30% weight	D38	B69Higher
Mission25% weight	Not scored	A83
Risk15% weight	D28	B69Higher
Tradability15% weight	C50	A95Higher
Holdings10% weight	D37	C45Higher
Durability5% weight	C50	A89Higher

Rank among Biotech & Genomics funds

How we build Categories ›

Same Category. GNOM and IBB are both graded against the same 17 Biotech & Genomics funds, so their Grades compare head to head.

Biotech & Genomics⁠

Category · 17 funds

See all 17 ›

IBB ranks 3rd and GNOM 14th of 17 funds in the Biotech & Genomics Category.

Rank 1AXBIState Street SPDR S&P Biotech ETFScore 80
Rank 2AIBBQInvesco Nasdaq Biotechnology ETFScore 77
Rank 3AIBBiShares Biotechnology ETFScore 75
Rank 4ABBPVirtus Biotech ETFScore 74
Rank 13DHELXFranklin Genomic Advancements ETFScore 39
Rank 14DGNOMGlobal X Genomics & Biotechnology ETFScore 38
Rank 15DARKGARK Genomic Revolution ETFScore 33

Our read on each fund

ETF.net Research

GNOMDGlobal X Genomics & Biotechnology ETF

IBBAiShares Biotechnology ETF

In short

GNOM Most biotech ETFs buy the whole drug industry. GNOM buys the genome: gene editing, sequencing, genetic therapies, computational genomics. About 50 global names, one idea, no hedging.

IBB Biotech's original index fund. Since 2001 IBB has packed the whole US biotech sector, roughly 250 names, into one line item for 0.44% a year, below what the typical biotech fund charges.

Stated mandate

GNOM GNOM seeks to track, before expenses, the performance of the Solactive Genomics Index by investing in companies positioned to benefit from advances in genomic science, including gene editing, sequencing, genetic therapies, computational genomics, and biotechnology.

IBB The Fund seeks to track an index composed of U.S.-listed equities focused on the biotechnology sector.

Why people hold it

GNOM A genuine pure play. The index targets companies tied to advances in genomic science (gene editing, sequencing, genetic therapies), not the broad pharma complex most biotech funds hold.globalxetfs.com
Concentrated on purpose: roughly 50 holdings, global reach. The theme drives the fund instead of being diluted by megacap drugmakers.globalxetfs.com
Running since 2019, it is one of the older dedicated genomics baskets, with a multi-year record through a full cycle in the theme.

IBB A 2001 launch makes it one of the sector's originals, and it has grown into a multi-billion-dollar fund that trades actively.
Roughly 250 stocks, so the whole US biotech bench comes along instead of a few marquee drugmakers.
0.44% a year, set by the prospectus and below the median fee in its biotech peer group.
Sticks closely to the job in its prospectus: US-listed biotech equities, nothing exotic bolted on. That lands it in the upper half of its peer group.ishares.com

Worth knowing

GNOM The narrow screen costs more: 0.50% a year, against 0.44% for IBB, 0.35% for XBI and 0.19% for IBBQ, which own biotech broadly.
Thinly traded next to the big biotech funds. Limit orders and mid-session trading matter more here than with a household-name ETF.
Small, clinical-stage genomics names swing hard, and with about 50 holdings there is nowhere to hide. Volatility is the price of the pure theme.

IBB Cheaper seats exist in the same aisle: IBBQ at 0.19%, BBP at 0.34%, XBI at 0.35%.
One industry carries the whole fund. Trial readouts, FDA decisions and patent expiries drive it, with no other sector to cushion a rough patch.
Distributions arrive quarterly, but biotech is a growth sector and payouts are a side effect, not the point.

Full GNOM profile⁠

Full IBB profile⁠

GNOM vs IBB Holdings

As of Oct 13, 2026

How GNOM and IBB differ

Overlap by weight

23.9%

Shared holdings make up 78.4% of GNOM and 35.9% of IBB.

Level by level

Sector7 Sectors0.0%
Holdings37 in both23.9%
Countryby domicile96.1%
Asset classEquity100%

Sector

Sector weights in GNOM and IBB, widest gap first
Sector	More in GNOMMore in IBB	GNOM	IBB
Health Care	GNOM +99.7 points	99.7%	0.0%
Biotechnology	IBB +87.5 points	0.0%	87.5%
Life Sciences Tools & Services	IBB +9.6 points	0.0%	9.6%
Pharmaceuticals	IBB +2.7 points	0.0%	2.7%
Technology	GNOM +0.3 points	0.3%	0.0%
Health Care Services	IBB +0.1 points	0.0%	0.1%
Health Care Equipment	IBB +0.1 points	0.0%	0.1%

Country, concentration and asset class

Country by domicile

Country weights in GNOM and IBB, widest gap first
Country	More in GNOMMore in IBB	GNOM	IBB
Switzerland	GNOM +2.3 points	2.5%	0.3%
Denmark	IBB +2.1 points	0.0%	2.1%
United States	GNOM +1.0 points	95.3%	94.3%
Netherlands	GNOM +0.7 points	1.0%	0.3%
Other countries (8)	IBB +1.8 points	1.2%	3.0%

Concentration

Weight in the 10 largest Holdings

GNOM55.7%
IBB51.4%

Securities held

GNOM50
IBB241

Asset class

GNOM: Equity
IBB: Equity

Holdings

Only in GNOM13
In both37
Only in IBB204

Only in GNOM

13 securities, 21.7% of GNOM by weight

Guardant Health Inc5.22%
Genscript Biotech Corp4.58%
Qiagen N.v.3.26%
Eli Lilly & Co1.83%
Billiontoone Inc Class A1.38%
Genedx Holdings Corp1.23%
Astrazeneca PLC1.16%
Danaher Corp1.06%
Bristol-Myers Squibb Co0.87%
Agilent Technologies Inc0.36%
Mesa Laboratories Inc0.27%
Quest Diagnostics Inc0.25%
Benitec Biopharma Inc0.22%

Only in IBB

204 securities, 64.0% of IBB by weight

Amgen Inc8.31%
Regeneron Pharmaceuticals6.24%
Argenx SE Adr3.36%
Biogen2.52%
Revolution Medicines2.50%
Genmab Sponsored Adr2.14%
Beone Medicines AG2.11%
United Therapeutics1.68%
Insmed1.64%
Incyte Corp1.64%
Alnylam Pharmaceuticals1.49%
Roivant Sciences Ltd1.31%
Charles River Laboratories Interna1.15%
Exelixis Inc1.13%
Ascendis Pharma1.05%
Halozyme Therapeutics1.00%
Neurocrine Biosciences1.00%
Medpace Holdings0.99%
Bridgebio Pharma0.89%
Repligen0.72%
Kymera Therapeutics0.64%
Madrigal Pharmaceuticals0.63%
Vaxcyte0.61%
Protagonist Therapeutics0.60%
Krystal Biotech0.58%
Cytokinetics0.57%
Tempus Ai Class A0.53%
Spyre Therapeutics Inc0.52%
Alkermes0.50%
Ionis Pharmaceuticals0.48%
Axsome Therapeutics0.43%
Abivax American Depositary Shares0.43%
Rhythm Pharmaceuticals0.41%
Grail Inc0.41%
Kodiak Sciences0.39%
Oruka Therapeutics0.39%
Cogent Biosciences0.33%
Ptc Therapeutics0.32%
Definium Therapeutics Inc0.32%
Travere Therapeutics0.31%
Mirum Pharmaceuticals0.31%
Scholar Rock Holding0.30%
Adaptive Biotechnologies0.28%
Cg Oncology0.26%
Erasca0.24%
Arcutis Biotherapeutics0.24%
Acadia Pharmaceuticals0.24%
Tarsus Pharmaceuticals0.24%
Xenon Pharmaceuticals0.23%
Iovance Biotherapeutics Inc0.23%

Weight gaps

All 37 Holdings in both funds, largest gap first.

Holding weights in GNOM and IBB, widest gap first
Holding	More in GNOMMore in IBB	GNOM	IBB
Gilead Sciences IncGILD	IBB +7.31 points	1.63%	8.94%
Twist Bioscience CorpTWST	GNOM +6.04 points	6.70%	0.66%
10X Genomics Inc-Class ATXG	GNOM +5.83 points	6.38%	0.55%
Moderna IncMRNA	GNOM +5.56 points	11.05%	5.49%
Vertex Pharmaceuticals IncVRTX	IBB +4.54 points	3.33%	7.87%
Illumina IncILMN	GNOM +3.68 points	6.09%	2.41%
Bio-Techne CorpTECH	GNOM +2.79 points	3.56%	0.77%
Caris Life Sciences IncCAI	GNOM +2.38 points	2.68%	0.30%
Crispr Therapeutics AGCRSP	GNOM +2.32 points	2.63%	0.31%
Veracyte IncVCYT	GNOM +2.30 points	2.57%	0.27%
Biomarin Pharmaceutical IncBMRN	GNOM +2.18 points	2.94%	0.76%
Biontech Se-AdrBNTX	GNOM +1.97 points	2.54%	0.57%
Caredx IncCDNA	GNOM +1.89 points	2.17%	0.28%
Arrowhead Pharmaceuticals InARWR	GNOM +1.82 points	2.36%	0.54%
Legend Biotech Corp-AdrLEGN	GNOM +1.73 points	1.97%	0.24%
Natera IncNTRA	GNOM +1.72 points	5.50%	3.78%
Praxis Precision Medicines IPRAX	GNOM +1.63 points	2.14%	0.51%
Beam Therapeutics IncBEAM	GNOM +1.58 points	1.75%	0.17%
Sarepta Therapeutics IncSRPT	GNOM +1.18 points	1.31%	0.13%
Ultragenyx Pharmaceutical InRARE	GNOM +0.97 points	1.07%	0.10%
Intellia Therapeutics IncNTLA	GNOM +0.95 points	1.06%	0.11%
Vir Biotechnology IncVIR	GNOM +0.88 points	0.98%	0.10%
Uniqure NVQURE	GNOM +0.80 points	0.91%	0.11%
Stoke Therapeutics IncSTOK	GNOM +0.74 points	0.84%	0.10%
Personalis IncPSNL	GNOM +0.73 points	0.81%	0.08%
Maravai Lifesciences Hldgs-AMRVI	GNOM +0.50 points	0.56%	0.06%
Pacific Biosciences of CalifPACB	GNOM +0.38 points	0.43%	0.05%
Wave Life Sciences IncWVE	GNOM +0.34 points	0.38%	0.04%
Fulgent Genetics IncFLGT	GNOM +0.30 points	0.32%	0.02%
Regenxbio IncRGNX	GNOM +0.24 points	0.27%	0.03%
Myriad Genetics IncMYGN	GNOM +0.24 points	0.28%	0.04%
Prime Medicine IncPRME	GNOM +0.23 points	0.26%	0.03%
Editas Medicine IncEDIT	GNOM +0.17 points	0.20%	0.03%
Rocket Pharmaceuticals IncRCKT	GNOM +0.17 points	0.19%	0.02%
Standard Biotools IncLAB	GNOM +0.13 points	0.15%	0.02%
Bruker CorpBRKR	IBB +0.12 points	0.31%	0.43%
Caribou Biosciences IncCRBU	GNOM +0.05 points	0.05%	<0.01%

All 50 GNOM holdings⁠All 243 IBB holdings⁠

How we measure overlap

Each holding counts at its smaller weight in the two funds, summed over the full Holdings. Sector, country and asset class use the same rule on each fund’s split. Cash, FX and derivative lines stay out of the counts. Two bond funds get no overlap figure.

GNOM vs IBB Cost

Overpaying GNOM vs IBB

$1,127

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

GNOM 0.50%
$9,979
IBB 0.44%
$8,852

Amount$10,000

Years30 years

Cost over time

GNOM 0.50%
IBB 0.44%
Overpaying

Year by year

Year	GNOM	IBB	Overpaying
10	$900	$794	$106
20	$3,460	$3,061	$399
30	$9,979	$8,852	$1,127

Expense ratio

0.50%GNOM
0.44%IBB, cheaper

IBB0.44%GNOM0.50%

0.19%0.75%

Middle half of Biotech & Genomics funds
Median 0.47%

IBB 6th cheapest of 17 funds

GNOM 10th cheapest of 17 funds

GNOM vs IBB Dividends

Last 12 months to Oct 30, 2026

Yield (12M): GNOM 0.93%, better; IBB 0.16%
Payout (12M): GNOM $0.65; IBB $0.34
Last payment: GNOM $0.06; IBB $0.01
Ex-dividend: GNOM Jun 29, 2026; IBB Sep 15, 2026
Paid on: GNOM Jul 7, 2026; IBB Sep 18, 2026
Frequency: GNOM Twice a year; IBB Quarterly

Distribution history

Per share, 2017 to 2026, same scale for both

GNOMTwice a year · 5 paymentsAll GNOM payments⁠

IBBQuarterly · 36 paymentsAll IBB payments⁠

GNOM vs IBB Risk

Fall from peak · 5 years

GNOM
IBB

Risk facts

VolatilityStd dev, 3 years: GNOM 30.0%IBB 17.9%, better
Return per unit of riskSharpe ratio, 3 years: GNOM 0.77IBB 1.07, better
Worst fallMax drawdown, 5 years: GNOM −68.9%IBB −35.7%, better
Market sensitivityBeta, 5 years: GNOM 1.60IBB 0.70; Market = 1

GNOM and IBB in the news

All news⁠

Deep Dive
Moderna fell 18% on cancer-vaccine data, and genomics ETFs fell 4%
Oct 23, 2026GNOMIBB
News
AstraZeneca agrees to invest $2 billion in Summit, without the drug rights
Sep 28, 2026IBB
Deep Dive
Health care's 1.8% week was four large caps, not a biotech rally
Sep 19, 2026IBB
Deep Dive
Health care ETFs spent 2026 between a 28% biotech rally and a 16% device slide
Sep 14, 2026IBB

Popular comparisons

GNOMDvsXBIA
Global X Genomics & Biotechnology ETF · State Street SPDR S&P Biotech ETF
Expense ratio
0.50% · 0.35%
Category
IBBAvsXBIA
iShares Biotechnology ETF · State Street SPDR S&P Biotech ETF
Expense ratio
0.44% · 0.35%
Category
GNOMDvsIBBQA
Global X Genomics & Biotechnology ETF · Invesco Nasdaq Biotechnology ETF
Expense ratio
0.50% · 0.19%
Category
IBBAvsIBBQA
iShares Biotechnology ETF · Invesco Nasdaq Biotechnology ETF
Expense ratio
0.44% · 0.19%
Category
GNOMDvsBBPA
Global X Genomics & Biotechnology ETF · Virtus Biotech ETF
Expense ratio
0.50% · 0.34%
Category
IBBAvsBBPA
iShares Biotechnology ETF · Virtus Biotech ETF
Expense ratio
0.44% · 0.34%
Category

GNOM vs IBB

In short

Stated mandate

Why people hold it